Company intelligence / Profile preview

Thallion Pharmaceuticals Inc.

Ownership: Private
Development stage: Phase 2

Overview

Thallion's lead program Shigamabs was a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections that completed a Phase II clinical trial. The company also had TLN-4601, a novel anti-cancer therapy that was in Phase II trials for glioblastoma multiforme.

Therapeutic areas: OncologyInfectious DiseasesNephrology
Modalities: Monoclonal antibodiesSmall molecules
Industry: Biotech

Drug pipeline

2 assets

diazepinomicin

1 more asset in the full pipeline.

Request access →

Partnerships

LFB Biotechnologies (terminated in 2013)Sunol Molecular Corp.

Beyond the preview

Go deeper on Thallion Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thallion Pharmaceuticals Inc..

Explore the full profile